FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	

1. Name and Address of Reporting Person [*] Shafmaster Madge K.			2. Issuer Name and Ticker or Trading Symbol <u>ProMIS Neurosciences Inc.</u> [PMN]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle)		· · · ·	3. Date of Earliest Transaction (Month/Day/Year) 06/12/2025		Director Officer (give title below)	10% Owner Other (specify below)			
C/O PROMIS NEUROSCIENCES INC. SUITE 200, 1920 YONGE STREET (Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv X	6. Individual or Joint/Group Filing (Check Applicable X Form filed by One Reporting Person Form filed by More than One Reporting Pe				
TORONTO	A6	M4S 3E2	_						
(City)	(State)	(Zip)	visition Securities Associated Dispessed of an Densfield						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

······································	2. Transaction Date (Month/Day/Year)	 3. Transac Code (Ir 8)					5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Option (right to buy)	\$0.5	06/12/2025		Α		20,000		(1)	06/12/2035	Common Shares	20,000	\$ <mark>0</mark>	20,000	D	

Explanation of Responses:

1. The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board.

/s/ Max Milbury, Attorney in Fact for Madge K. Shafmaster 06/16/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.